Early and intermediate-term outcomes with drug-eluting stents in high-risk patientswith symptomatic intracranial stenosis

Neurosurgery

Volumn 59, Issue 5, 2006, Pages 1044-1051

  Qureshi, Adnan I ^a,b   Kirmani, Jawad F ^a   Hussein, Haitham M ^a   Harris Lane, Pansy ^a   Divani, Afshin A ^a   Suri, M Fareed K ^a   Janjua, Nazli ^a   Alkawi, Ammar ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b NEUROLOGICAL INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Angioplasty; Intracranial atherosclerosis; Ischemic stroke; Stent; Transient ischemic attack

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PACLITAXEL; RAPAMYCIN; TICLOPIDINE; WARFARIN;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; BASILAR ARTERY; CAROTID ARTERY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DEATH; DRUG ELUTING STENT; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTERNAL CAROTID ARTERY OCCLUSION; INTRACRANIAL ARTERY STENOSIS; KAPLAN MEIER METHOD; MALE; MIDDLE CEREBRAL ARTERY; OCCLUSIVE CEREBROVASCULAR DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; RESTENOSIS; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; TREATMENT FAILURE; VERTEBRAL ARTERY; VERTEBRAL ARTERY STENOSIS;

BLOOD VESSEL PROSTHESIS; CEREBRAL INFARCTION; DRUG IMPLANTS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RISK ASSESSMENT; STENTS; TREATMENT OUTCOME;

EID: 33845219438     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000245593.54204.99     Document Type: Article

References (29)

1. Akins PT, Pilgram TK, Cross DT 3rd, Moran CJ: Natural history of stenosis from intracranial atherosclerosis by serial angiography. Stroke 29:433-438, 1998.
2. Bogousslavsky J, Barnett HJ, Fox AJ, Hachinski VC, Taylor W: Atherosclerotic disease of the middle cerebral artery. Stroke 17:1112-1120, 1986.
3. Chimowitz MI, Kokkinos J, Strong J, Brown MB, Levine SR, Silliman S, Pessin MS, Weichel E, Sila CA, Furlan AJ, Kargman DE, Sacco RL, Wityk RL, Ford G, Fayad PB: The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology 45:1488-1493, 1995.
4. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG, Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators: Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 352:1305-1316, 2005.
5. Clark WM, Barnwell SL, Nesbit G, O'Neill OR, Wynn ML, Coull BM: Safety and efficacy of percutaneous transluminal angioplasty for intracranial atherosclerotic stenosis. Stroke 26:1200-1204, 1995.
6. Doggrell SA: Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis. Expert Opin Pharmacother 5:2209-2220, 2004.
7. Garas SM, Huber P, Scott NA: Overview of therapies for prevention of restenosis after coronary interventions. Pharmacol Ther 92:165-178, 2001.
8. Gomez CR, Misra VK, Liu MW, Wadlington VR, Terry JB, Tulyapronchote R, Campbell MS: Elective stenting of symptomatic basilar artery stenosis. Stroke 31:95-99, 2000.
9. Higashida RT, Tsai FY, Halbach VV, Dowd CF, Smith T, Fraser K, Hieshima GB: Transluminal angioplasty for atherosclerotic disease of the vertebral and basilar arteries. J Neurosurg 78:192-198, 1993.
10. Holmes DR Jr, Vlietstra RE, Smith HC, Vetrovec GW, Kent KM, Cowley MJ, Faxon DP, Gruentzig AR, Kelsey SF, Detre KM, van Raden MJ, Mock MB: Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 53:77C-81C, 1984.
11. Isenbarger DW, Resar JR: Drug-eluting versus third-generation bare metal stents: The US strategy. Int J Cardiovasc Intervent 7:171-175, 2005.
12. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, Bernheim A, Zutter A, Zellweger M, Grize L, Pfisterer ME, BASKET Investigators: Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: Randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 366:921-929, 2005.
13. Kasner SE, Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Benesch CG, Sila CA, Jovin TG, Romano JG, Cloft HJ, Warfarin-Aspirin Symptomatic Disease Trial Investigators: Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation 113:555-563, 2006.
14. Klein LW: Are drug-eluting stents the preferred treatment for multivessel coronary artery disease? J Am Coll Cardiol 47:22-26, 2006.
15. Lang TA, Secic M: How to Report Statistics in Medicine. Annotated Guidelines for Authors, Editors and Reviewers. Philadelphia, American College of Physicians, 1997.
16. Liuzzo JP, Ambrose JA, Coppola JT: Sirolimus- and taxol-eluting stents differ towards intimal hyperplasia and re-endothelialization. J Invasive Cardiol 17:497-502, 2005.
17. Marks MP, Marcellus M, Norbash AM, Steinberg GK, Tong D, Albers GW: Outcome of angioplasty for atherosclerotic intracranial stenosis. Stroke 30:1065-1069, 1999.
18. Mori T, Kazita K, Chokyu K, Mima T, Mori K: Short-term arteriographic and clinical outcome after cerebral angioplasty and stenting for intracranial vertebrobasilar and carotid atherosclerotic occlusive disease. AJNR Am J Neuroradiol 21:249-254, 2000.
19. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP, Quality Trial Investigators: Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: The REALITY trial - A randomized controlled trial. JAMA 295:895-904, 2006.
20. Popma JJ, Leon MB, Moses JW, Holmes DR Jr, Cox N, Fitzpatrick M, Douglas J, Lambert C, Mooney M, Yakubov S, Kuntz RE, SIRIUS Investigators: Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation 110:3773-3780, 2004.
21. Qureshi AI, Luft AR, Sharma M, Guterman LR, Hopkins LN: Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: Part II - Clinical aspects and recommendations. Neurosurgery 46:1360-1375, 2000.
22. Qureshi AI, Suri MF, Siddiqui AM, Kim SH, Boulos AS, Ringer AJ, Lopes DK, Guterman LR, Hopkins LN: Clinical and angiographic results of dilatation procedures for symptomatic intracranial atherosclerotic disease. J Neuroimaging 15:240-249, 2005.
23. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML: Thrombolysis in Myocardial Infarction (TIMI) Trial: Phase I - Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:1-11, 1988.
24. Sacco RL, Kargman DE, Gu Q, Zamanillo MC: Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke 26:14-20, 1995.
25. Sehgal SN: Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc 35:7S-14S, 2003.
26. SSYLVIA Study Investigators: Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): Study results. Stroke 35:1388-1392, 2004.
27. Thijs VN, Albers GW: Symptomatic intracranial atherosclerosis: Outcome of patients who fail antithrombotic therapy. Neurology 55:490-497, 2000.
28. Wityk RJ, Lehman D, Klag M, Coresh J, Ahn H, Litt B: Race and sex differences in the distribution of cerebral atherosclerosis. Stroke 27:1974-1980, 1996.
29. Wolfe CD, Taub NA, Woodrow EJ, Burney PG: Assessment of scales of disability and handicap for stroke patients. Stroke 22:1242-1244, 1991.